Immuron (IMRN) Operating Margin (2016 - 2024)
Immuron (IMRN) posted quarterly Operating Margin of 20861481670048.55% for Q4 2024, up 2086148167013430.0% year-on-year from N/an in Q1 2024, and up 24326835564920.37% on a QoQ basis from 85.76% in Q4 2023.
Immuron (IMRN) Operating Margin (2016 - 2024) Analysis & Trends
Immuron (IMRN) has reported Operating Margin for 9 consecutive years, with 20861481670048.55% the latest figure, recorded in Q4 2024.
- Quarterly Operating Margin rose 2086148167013430.0% year-over-year to 20861481670048.55% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 15427999199939.01% (up 1542799962463987.8% YoY) and the FY2025 annual result came in at 73.34%, up 4498.0% from the prior year.
- Operating Margin rose to 20861481670048.55% in Q4 2024 per IMRN's latest filing, from 85.76% in the prior quarter.
- Over the last five years, Operating Margin for IMRN reached as high as 20861481670048.55% in Q4 2024 and fell as low as 788216345.4% in Q4 2021.
- A 5-year average of 3476715574435.75% and a median of 913.29% in 2022 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2020 — Operating Margin slumped 2000000000 bps — and 2024, when it soared 2000000000 bps.
- Year by year, Operating Margin stood at 400005176.34% in 2020, then slumped by 97 bps to 788216345.4% in 2021, then surged by 100 bps to 331.75% in 2022, then soared by 74 bps to 85.76% in 2023, then jumped by 2000000000 bps to 20861481670048.55% in 2024.
- According to Business Quant data, Operating Margin over the past three periods registered 20861481670048.55%, 85.76%, and 1494.83% for Q4 2024, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 20,861,481,670,048.55% |
| Dec 31, 2023 | -85.76% |
| Jun 30, 2023 | -1,494.83% |
| Dec 31, 2022 | -331.75% |
| Dec 31, 2021 | -788,216,345.40% |
| Dec 31, 2020 | -400,005,176.34% |
| Dec 31, 2019 | -636,308.73% |
| Dec 31, 2018 | -161.71% |
| Dec 31, 2017 | 401.31% |
| Dec 31, 2016 | 481.82% |
| Jun 30, 2016 | 501.82% |